Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2005

View Archived Issues

Second interim analysis of phenserine tartrate study in Alzheimer's disease

CholeraGarde reported safe and immunogenic in children and infants

A phase III study confirms the efficacy of telbivudine in compensated chronic hepatitis B

Posiphen given green light to begin phase I

Human Genome Sciences receives milestone payment for GSK-716155

Antiinflammatory compound QR-440 shows disease-modifying potential

BioMarin submits Orapred ODT NDA

Fast track designation for panitumumab for metastatic colorectal cancer

MN-166 enters phase II study for relapsing-remitting MS

Solvay and Berna Biotech sign Aerugen license agreement

Novel compounds inhibit D816 Kit mutation tumor growth

UK-290795: an NK2 antagonist with greater oral absorption

RO-4383596 demonstrates antiangiogenic and antitumor effects

Oracea NDA filed

Peplin raises funds for leukemia program of PEP-005 IV

Kyorin and LG Life Sciences sign memorandum of understanding for KRP-197

Provisional patent application on novel anticancer compounds

Novel analgesic agents claimed in recent patent literature

Therapeutic benefits found for XP-13512 in RLS

Ghrelin increases acute energy intake in malnourished peritoneal dialysis patients

Positive benefits of coenzyme Q10 in Parkinson's disease

Synergistic effects reported for tipifarnib plus taxanes in multiple myeloma

New targets and treatments reported for psychosis, depression, etc.

iNOS inhibitors prepared and tested by Altana Pharma

Antiplatelet effects reported for S-18886 in patients with peripheral artery disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...